Dr. Awh Presents 4D-150 Gene Therapy Data at ASRS 2026
Dr. Carl Awh Presents Two-Year Gene Therapy Findings for Wet AMD at ASRS 2026
New research highlights the potential for investigational gene therapy to reduce treatment burden for patients with wet age-related macular degeneration (AMD).
Carl C. Awh, MD, FASRS, President of Tennessee Retina, presented two-year findings on 4D-150, an investigational gene therapy for wet AMD, at the 2026 American Society of Retina Specialists (ASRS) Annual Meeting in Montreal, Canada.
Featured in Ophthalmology Times and discussed in a video interview with Eye Care Network, the findings highlight the potential for gene therapy to reduce the need for repeated eye injections while maintaining vision and retinal anatomy.
4D-150 Gene Therapy 2-Year Wet AMD Data
Carl C. Awh. MD, FASRS
Two-Year Findings Show Potential to Reduce Treatment Burden
Wet AMD often requires ongoing anti-VEGF injections to control abnormal blood vessel growth and help preserve vision. Although these treatments have transformed care, frequent appointments can create challenges for patients over time.
4D-150, developed by 4D Molecular Therapeutics, is designed to provide sustained therapeutic activity following a single injection.
In his ASRS presentation, Dr. Awh highlighted results among patients with more moderate disease and those with recently diagnosed wet AMD. Among patients whose disease duration was less than two years, approximately half did not require another injection during the two-year follow-up period. In a subgroup with more recently diagnosed disease, 87% went two years without an additional injection.
These findings suggest the potential for a meaningful reduction in treatment burden for some patients while maintaining visual and anatomical outcomes.
Safety and Future Research
Dr. Awh also discussed safety data, with follow-up extending to four years in some patients. Two eyes experienced mild inflammation within the first 28 weeks after treatment, which was managed with topical therapy.
Although the findings are encouraging, 4D-150 remains investigational and is not an approved treatment for wet AMD. Phase 3 clinical trials will help further evaluate its safety and effectiveness.
Advancing the Future of Retinal Care
Dr. Awh's presentation reflects the ongoing work to explore new approaches to retinal disease management and reduce the challenges associated with long-term treatment.
Read the full article from Ophthalmology Times: ASRS 2026-Carl C. Awh, MD, FASRS
